Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Inclusion Criteria:

Main criteria:

- Postmenopausal women (hysterectomized or not)

- Women between 40 and 80 years of age

- Women having ≤5% of superficial cells on vaginal smear at baseline

- Women having a vaginal pH above 5 at baseline

- Women who have self-identified moderate or severe symptom(s) of vaginal atrophy

- Willing to participate in the study and sign an informed consent

Exclusion Criteria:

Main criteria:

- Previous enrollment in EndoCeutics studies performed with intravaginal DHEA

- Previous diagnosis of cancer, except skin cancer (non melanoma)

- Clinically significant metabolic or endocrine disease (including diabetes mellitus)
not controlled by medication

- The administration of any investigational drug within 30 days of screening visit

- Clinically significant abnormal serum biochemistry, urinalysis or hematology